Protalix BioTherapeutics Inc (PLX)

1.78 +0.05 (+2.89%) USD  |  NYAM  |  Dec 24, 16:00
More

Protalix BioTherapeutics Research and Development Expense (Quarterly): 2.998M for Sept. 30, 2024

Research and Development Expense (Quarterly) Chart

View Research and Development Expense (Quarterly) for PLX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (Quarterly) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

R&D Expense Definition

View R&D Expense Definition
Start Trial

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Quarterly) Range, Past 5 Years

View Research and Development Expense (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (Quarterly) Benchmarks

View Research and Development Expense (Quarterly) Benchmarks
Start Trial
Accuray Inc 12.12M
AIM ImmunoTech Inc 1.437M
Perspective Therapeutics Inc 12.03M
Electromed Inc 0.166M
Armata Pharmaceuticals Inc 9.485M